Last reviewed · How we verify
NCT02721472: PADRE
Plasma DNA and Vascular Remodelling in Patients With Sickle Cell Disease
NA trial testing micro- and macro-circulatory vascular remodelling measures not practice in routine care in Sickle Cell Disease in 44 participants. Completed in 14 November 2019.
14 November 2019
Quick facts
| Lead sponsor | Theravia |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 44 |
| Start date | 17 May 2016 |
| Primary completion | 14 November 2019 |
| Estimated completion | 14 November 2019 |
| Sites | 1 location across France |
Drugs / interventions tested
- micro- and macro-circulatory vascular remodelling measures not practice in routine care
- Biological measures not practice in routine care
Conditions studied
- Sickle Cell Disease — all drugs for Sickle Cell Disease →
Sponsor
Theravia — full company profile →
Who can join
18 and older, any sex, with Sickle Cell Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the relationship between plasma DNA levels and micro- and macro-circulatory vascular remodelling in patients with sickle cell disease
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02721472
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sickle Cell Disease
Currently open trials in the same condition.
- NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
- NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
- NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
- NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
- NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting
Other Theravia trials
Trials by the same sponsor.
- NCT05470270 — Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease. · Phase 2 · completed
- NCT05025072 — A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Siklos® in Healthy Volunteers · Phase 1 · completed
- NCT04707235 — ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension Study · active not recruiting
- NCT03806452 — SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial) · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02721472 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Theravia
- Last refreshed: 9 January 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02721472.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing